Evaluation of the Diagnostic Properties of Serum hsa-miR-223-5p in the Detection of Gastric Cancer: A Case-Control Study

Author(s): Amir H. Aalami, Vahid Pouresmaeil*, Amir Amirabadi, Fatemeh H. Mojahed, Mahdi Q. Rad, Amirhossein Sahebkar*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 20 , Issue 7 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: MicroRNAs (miRs) are a group of small non-coding and single-stranded RNAs of 18 to 25 nucleotides. The study of microRNAs is one of the new ways to detect cancer. In this study, the serum expression of miR-223 in patients with GC was measured and compared with the control group.

Methods: This case-control study was conducted on 39 patients with GC and 39 control subjects who visited the Reza Radiotherapy and Oncology Center, Mashhad, Iran, due to gastrointestinal complaints. The demographic information was collected, and the serum levels of miR-223 were measured using the real-time PCR technique in all study subjects. The association between the GC of miR-223 and tumor staging and cancer progression was assessed.

Results: The miR-223 expression in GC patients was 3.10-fold higher than that of the control group (p<0.0001). The miR-223 expression was significantly higher in the GC stages and grades compared to the control group (p<0.0001 each). However, there was no significant effect for age, smoking, and gender on miR- 223 expression in GC and controls. At the optimal cutoff value of 0.7436, the maximal sensitivity of 89.74% and specificity of 84.62% were achieved for miR-223 (p<0.001). The sensitivity and specificity for miR-223 for differentiating low grades from high grade were 92.31% and 73.08% (p=0.0003), and for differentiating low stages from the high stage was 81.82% and 39.29% respectively (p=0.696).

Conclusion: This study revealed that miR-223 could be considered as a non-invasive diagnostic marker in the early diagnosis of GC.

Keywords: Gastric cancer, microRNA, miR-223, diagnostic, serum, real-time PCR.

[1]
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
[2]
Kim, M.; Kasinski, A.L.; Slack, F.J. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol., 2011, 12(4), 319-321.
[http://dx.doi.org/10.1016/S1470-2045(11)70067-5] [PMID: 21463831]
[3]
Li, M.; Li, J.; Ding, X.; He, M.; Cheng, S-Y. microRNA and cancer. AAPS J., 2010, 12(3), 309-317.
[http://dx.doi.org/10.1208/s12248-010-9194-0] [PMID: 20422339]
[4]
Tarver, T. Cancer facts and figures 2014. J. Consum. Health Internet, 2012, 16, 366-367.
[http://dx.doi.org/10.1080/15398285.2012.701177]
[5]
Binato, R.; Santos, E.C.; Boroni, M.; Demachki, S.; Assumpção, P.; Abdelhay, E. A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis. Oncotarget, 2017, 9(7), 7359-7371.
[PMID: 29484116]
[6]
Behnampour, N.; Hajizadeh, E.; Zayeri, F.; Semnani, S. Modeling of influential predictors of gastric cancer incidence rates in Golestan province, North Iran. Asian Pac. J. Cancer Prev., 2014, 15(3), 1111-1117.
[http://dx.doi.org/10.7314/APJCP.2014.15.3.1111] [PMID: 24606427]
[7]
Sitarz, R.; Skierucha, M.; Mielko, J.; Offerhaus, G.J.A.; Maciejewski, R.; Polkowski, W.P. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag. Res., 2018, 10, 239-248.
[http://dx.doi.org/10.2147/CMAR.S149619] [PMID: 29445300]
[8]
Seidlitz, T.; Merker, S.R.; Rothe, A.; Zakrzewski, F.; von Neubeck, C.; Grützmann, K.; Sommer, U.; Schweitzer, C.; Schölch, S.; Uhlemann, H.; Gaebler, A.M.; Werner, K.; Krause, M.; Baretton, G.B.; Welsch, T.; Koo, B.K.; Aust, D.E.; Klink, B.; Weitz, J.; Stange, D.E. Human gastric cancer modelling using organoids. Gut, 2019, 68(2), 207-217.
[http://dx.doi.org/10.1136/gutjnl-2017-314549] [PMID: 29703791]
[9]
Jenabi, E.; Saatchi, M.; Khazaei, S.; Mansori, K.; Ayubi, E.; Soheylizad, M.; Khazaei, L.; Nematollahi, S.; Beigi, A.M. National distribution of stomach cancer incidence in Iran: A population-based study. Adv. Human Biol., 2019, 9(1), 89.
[http://dx.doi.org/10.4103/AIHB.AIHB_37_18]
[10]
Ajani, J.A.; D’Amico, T.A.; Almhanna, K.; Bentrem, D.J.; Chao, J.; Das, P.; Denlinger, C.S.; Fanta, P.; Farjah, F.; Fuchs, C.S.; Gerdes, H.; Gibson, M.; Glasgow, R.E.; Hayman, J.A.; Hochwald, S.; Hofstetter, W.L.; Ilson, D.H.; Jaroszewski, D.; Johung, K.L.; Keswani, R.N.; Kleinberg, L.R.; Korn, W.M.; Leong, S.; Linn, C.; Lockhart, A.C.; Ly, Q.P.; Mulcahy, M.F.; Orringer, M.B.; Perry, K.A.; Poultsides, G.A.; Scott, W.J.; Strong, V.E.; Washington, M.K.; Weksler, B.; Willett, C.G.; Wright, C.D.; Zelman, D.; McMillian, N.; Sundar, H. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2016, 14(10), 1286-1312.
[http://dx.doi.org/10.6004/jnccn.2016.0137] [PMID: 27697982]
[11]
Arai, Y.; Ogawa, O. Hormone Therapy and Castration Resistance of Prostate Cancer; Springer, 2018.
[http://dx.doi.org/10.1007/978-981-10-7013-6]
[12]
Lu, T.X.; Rothenberg, M.E.; Micro, R.N.A. MicroRNA. J. Allergy Clin. Immunol., 2018, 141(4), 1202-1207.
[http://dx.doi.org/10.1016/j.jaci.2017.08.034] [PMID: 29074454]
[13]
Parto, P.; Masoudian, N. The expansion of Micro-RNA 21 (miR-21) in the serum of patients with gastric cancer. J. Ilam Univ. Med. Sci., 2016, 23(6), 10-19.
[14]
Dwivedi, S.; Purohit, P.; Sharma, P. MicroRNAs and Diseases: Promising Biomarkers for Diagnosis and Therapeutics; Springer, 2019.
[15]
Wen, D.; Qiao, P.; Wang, L. Circulating microRNA-223 as a potential biomarker for obesity. Obes. Res. Clin. Pract., 2015, 9(4), 398-404.
[http://dx.doi.org/10.1016/j.orcp.2015.01.006] [PMID: 25842981]
[16]
Wang, J.; Wu, J.; Cheng, Y.; Jiang, Y.; Li, G. Over-expression of microRNA-223 inhibited the proinflammatory responses in Helicobacter pylori-infection macrophages by down-regulating IRAK-1. Am. J. Transl. Res., 2016, 8(2), 615-622.
[PMID: 27158353]
[17]
Wang, H.; Wang, L.; Wu, Z.; Sun, R.; Jin, H.; Ma, J.; Liu, L.; Ling, R.; Yi, J.; Wang, L.; Bian, J.; Chen, J.; Li, N.; Yuan, S.; Yun, J. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med. Oncol., 2014, 31(12), 298.
[http://dx.doi.org/10.1007/s12032-014-0298-8] [PMID: 25367852]
[18]
Li, X.; Zhang, Y.; Zhang, H.; Liu, X.; Gong, T.; Li, M.; Sun, L.; Ji, G.; Shi, Y.; Han, Z.; Han, S.; Nie, Y.; Chen, X.; Zhao, Q.; Ding, J.; Wu, K.; Daiming, F. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol. Cancer Res., 2011, 9(7), 824-833.
[http://dx.doi.org/10.1158/1541-7786.MCR-10-0529] [PMID: 21628394]
[19]
Link, A.; Schirrmeister, W.; Langner, C.; Varbanova, M.; Bornschein, J.; Wex, T.; Malfertheiner, P. Differential expression of microRNAs in preneoplastic gastric mucosa. Sci. Rep., 2015, 5, 8270.
[http://dx.doi.org/10.1038/srep08270] [PMID: 25652892]
[20]
Fassan, M.; Saraggi, D.; Balsamo, L.; Realdon, S.; Scarpa, M.; Castoro, C.; Coati, I.; Salmaso, R.; Farinati, F.; Guzzardo, V.; Arcidiacono, D.; Munari, G.; Gasparini, P.; Veronese, N.; Luchini, C.; Valeri, N.; Rugge, M. Early miR-223 upregulation in gastroesophageal carcinogenesis. Am. J. Clin. Pathol., 2017, 147(3), 301-308.
[http://dx.doi.org/10.1093/ajcp/aqx004] [PMID: 28395057]
[21]
Juzėnas, S.; Saltenienė, V.; Kupcinskas, J.; Link, A.; Kiudelis, G.; Jonaitis, L.; Jarmalaite, S.; Kupcinskas, L.; Malfertheiner, P.; Skieceviciene, J. Analysis of deregulated microRNAs and their target genes in gastric cancer. PLoS One, 2015, 10(7), e0132327
[http://dx.doi.org/10.1371/journal.pone.0132327] [PMID: 26172537]
[22]
Li, B.S.; Zhao, Y.L.; Guo, G.; Li, W.; Zhu, E.D.; Luo, X.; Mao, X.H.; Zou, Q.M.; Yu, P.W.; Zuo, Q.F.; Li, N.; Tang, B.; Liu, K.Y.; Xiao, B. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One, 2012, 7(7), e41629
[http://dx.doi.org/10.1371/journal.pone.0041629] [PMID: 22860003]
[23]
Haneklaus, M.; Gerlic, M.; O’Neill, L.A.; Masters, S.L. miR-223: infection, inflammation and cancer. J. Intern. Med., 2013, 274(3), 215-226.
[http://dx.doi.org/10.1111/joim.12099] [PMID: 23772809]
[24]
Liu, H-S.; Xiao, H-S. MicroRNAs as potential biomarkers for gastric cancer. World J. Gastroenterol., 2014, 20(34), 12007-12017.
[http://dx.doi.org/10.3748/wjg.v20.i34.12007] [PMID: 25232237]
[25]
Gao, Y.; Lin, L.; Li, T.; Yang, J.; Wei, Y. The role of miRNA-223 in cancer: Function, diagnosis and therapy. Gene, 2017, 616, 1-7.
[http://dx.doi.org/10.1016/j.gene.2017.03.021] [PMID: 28322994]
[26]
Li, J.; Guo, Y.; Liang, X.; Sun, M.; Wang, G.; De, W.; Wu, W. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J. Cancer Res. Clin. Oncol., 2012, 138(5), 763-774.
[http://dx.doi.org/10.1007/s00432-012-1154-x] [PMID: 22270966]
[27]
Zheng, Y.; Cui, L.; Sun, W.; Zhou, H.; Yuan, X.; Huo, M.; Chen, J.; Lou, Y.; Guo, J. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark., 2011-2012, 10(2), 71-77.
[http://dx.doi.org/10.3233/CBM-2011-0231] [PMID: 22430134]
[28]
Zhou, X.; Ji, G.; Chen, H.; Jin, W.; Yin, C.; Zhang, G. Clinical role of circulating miR-223 as a novel biomarker in early diagnosis of cancer patients. Int. J. Clin. Exp. Med., 2015, 8(9), 16890-16898.
[PMID: 26629240]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 7
Year: 2020
Published on: 02 July, 2020
Page: [800 - 808]
Pages: 9
DOI: 10.2174/1871520620666200204100602
Price: $65

Article Metrics

PDF: 22
HTML: 2